Praxis Precision Medicines Inc.
Praxis Precision Medicines Updates Clinical Programs and Corporate Presentation
Summary
Praxis Precision Medicines, Inc. updated its corporate presentation on May 2, 2025, and provided updates on its clinical programs, including new data from the EMBOLD study showing sustained seizure reduction in patients with SCN2A gain-of-function and SCN8A developmental and epileptic encephalopathies (DEEs) and announced the trial design for its EMERALD study. The company also announced plans to nominate a development candidate for its early-stage antisense oligonucleotide program, PRAX-100, in mid-2025. The corporate presentation is available on the company's website.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement